Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
Brief pharmaceutical news items for July 2009.

Pharmaceutical Technology
Volume 33, Issue 7, pp. 90

Q&A with Gerry Migliaccio, vice-president of quality; environment, health, and safety; and agility at Pfizer

PharmTech:



What is the biggest industry challenge you're now facing?

Migliaccio:

The pharmaceutical industry is facing the same challenges as many other industries as a result of the economic situation, plus a few unique challenges such as successfully bringing new medicines to market and changing payors' expectations. From the pharmaceutical manufacturing perspective, I think one of our biggest challenges is securing our supply chains as they become truly global. The challenge includes the prevention and detection of counterfeits, the prevention of product diversion, and the prevention of intentional (i.e., criminal) adulteration.

PharmTech:

How do you stay abreast of new developments in the industry?

Migliaccio:

I try to interact with industry colleagues and regulators as often as possible at industry association meetings, which is where you can get a true sense of new developments from the perspective of industry and the regulatory agencies. For my daily dose of current industry affairs, I review Dickinson's FDA Webview and several other online newsletters.

PharmTech:

Do you see a new industry trend emerging?

Migliaccio:

I see quite a few trends in the manufacturing arena. The trend toward outsourcing will continue. Strategies widely used in other industries such as continuous processing are taking hold in pharmaceutical manufacturing and will emerge in the coming years. As quality by design continues to be adopted and our manufacturing processes become better understood and highly capable, reliance on product testing will be reduced significantly.

Gerry Migliaccio will be a keynote speaker at Pharmaceutical Technology's Third Annual Conference to be held Aug. 11–12, 2009, in Philadelphia. For program details and to register, visit http://www.pharmtechevent.com


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here